Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.

被引：0

作者：

Shen, Bo ^{[1
]}

Wu, Yuan ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Internal Med Oncol, Nanjing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

703

引用

页码：703 / 703

页数：1

共 50 条

[31] Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial
Qin, B.
Zhai, J.
Lu, D.
Ge, X.
Mao, Y.
Sheng, S.
Hu, Y.
Wang, J.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S321 - S322
[32] Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma The CAP 03 Phase 2 Nonrandomized Clinical Trial
Mao, Lili
Lian, Bin
Li, Caili
Bai, Xue
Zhou, Li
Cui, Chuanliang
Chi, Zhihong
Sheng, Xinan
Wang, Xuan
Tang, Bixia
Yan, Xieqiao
Li, Siming
Kong, Yan
Dai, Jie
Wei, Xiaoting
Li, Juan
Duan, Rong
Xu, Huayan
Wu, Xiaowen
Yang, Yue
Cheng, Fengzhuo
Zhang, Cheng
Xia, Fangzhou
Pang, Zheng
Guo, Jun
Si, Lu
JAMA ONCOLOGY, 2023, 9 (08) : 1099 - 1107
[33] Biomarker analysis of first-line camrelizumab plus apatinib in patients with advanced biliary tract cancers: Results from a phase II study.
Rao, Jian-Hua
Chen, Dong-Sheng
Song, Yunjie
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16164 - E16164
[34] Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer.
Prithviraj, Gopi Kesaria
Baksh, Kathryn Anissa
Fulp, William J.
Meredith, Ken
Hoffe, Sarah E.
Shridhar, Ravi
Almhanna, Khaldoun
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[35] Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
Wang, Huaying
Tian, Wenjuan
Ren, Yulan
Jing, Chuyu
Shan, Boer
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[36] First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
Chen, Xiaofeng
Xu, Hao
Chen, Xiaobing
Xu, Tongpeng
Tian, Yitong
Wang, Deqiang
Guo, Fen
Wang, Kangxin
Jin, Guangfu
Li, Xiao
Wang, Rong
Li, Fengyuan
Ding, Yongbin
Tang, Jie
Fang, Yueyu
Zhao, Jing
Liu, Liang
Ma, Ling
Meng, Lijuan
Hou, Zhiguo
Zheng, Rongrong
Liu, Yang
Guan, Ni
Zhang, Bei
Tong, Shuang
Chen, Shiqing
Li, Xing
Shu, Yongqian
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
[37] Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer
Schwartzberg, Lee S.
Arena, Francis P.
Mintzer, David M.
Epperson, Amanda L.
Walker, Mark S.
CLINICAL BREAST CANCER, 2012, 12 (02) : 87 - 93
[38] Combined Therapy With Gemcitabine Hydrochloride and Nanoparticle Albumin-bound Paclitaxel Enabled Resection in a Patient With Unresectable Locally Advanced Pancreatic Cancer
Sakaue, Takahiko
Fukahori, Masaru
Miwa, Keisuke
Ushijima, Tomoyuki
Yasumoto, Makiko
Kuraoka, Kei
Ishida, Yuusuke
Nagasu, Sachiko
Ishikawa, Hiroto
Mihara, Yuutarou
Nakayama, Masamichi
Naitou, Yoshiki
Okabe, Yoshinobu
Torimura, Takuji
PANCREAS, 2019, 48 (06) : 859 - 859
[39] Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
Srinivasan, K. N.
Rauthan, Amit
Gopal, R.
CASE REPORTS IN ONCOLOGICAL MEDICINE, 2014, 2014
[40] First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer.
Shi, Jian
Liu, Jiayin
Duan, Xiaoyang
Huang, Guanglei
Wang, Lixing
Zhao, Yan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →